Author

Andrew M. Bellinger

Verve Therapeutics (United States)ORCID 0000-0002-3235-2313Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:non-human primate· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Aaron Beach· 1 shared Alexandra C. ChadwickiD· 1 shared Anne Marie MazzolaiD· 1 shared Chaitali Dutta· 1 shared Christopher Cheng· 1 shared Ellen Rohde· 1 shared Huilan Ren· 1 shared Kallanthottathil G. RajeeviD· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetics

Aaron Beach

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

GeneticsbioRxivPreprintNov 8, 2021

Lipid nanoparticles incorporating a GalNAc ligand enable in vivo liver ANGPTL3 editing in wild-type and somatic LDLR knockout non-human primates

Lisa N. Kasiewicz, Souvik Biswas, Aaron Beach…·Andrew M. Bellinger

This study develops GalNAc-LNPs for liver gene editing in NHPs, achieving high editing efficiency and ANGPTL3 reduction in both HoFH and wild-type models.

5 citations

non-human primateCRISPR screen

𝕏 PostBluesky